Industry Comparison

Select Language
Current language: English (2023)

You are viewing information about the following Industries:

  • Electronic Manufacturing Services & Original Design Manufacturing The Electronic Manufacturing Services (EMS) & Original Design Manufacturing (ODM) industry consists of two main segments. EMS entities provide assembly, logistics and after-market services for original equipment manufacturers. ODM entities provide engineering and design services for original equipment manufacturers and may own significant intellectual property. Although EMS & ODM entities produce equipment for a variety of sectors, the industry is associated closely with the Hardware industry, which consists of entities that design technology hardware products such as personal computers, consumer electronics and storage devices for both personal consumers and businesses.
      Remove
  • Biotechnology & Pharmaceuticals The Biotechnology & Pharmaceuticals industry develops, manufactures, and markets a range of brand-name and generic medications. A significant portion of the industry is driven by research and development, a high risk of product failure during clinical trials, and the need to obtain regulatory approval. Concerns over pricing practices and consolidation within the sector have created downward pricing pressures. Demand for the industry’s products is largely driving by population demographics, rates of insurance coverage, disease profiles, and economic conditions.
      Remove

Relevant Issues for both Industries (14 of 26)

Why are some issues greyed out? The SASB Standards vary by industry based on the different sustainability-related risks and opportunities within an industry. The issues in grey were not identified during the standard-setting process as the most likely to be useful to investors, so they are not included in the Standard. Over time, as the ISSB continues to receive market feedback, some issues may be added or removed from the Standard. Each company determines which sustainability-related risks and opportunities are relevant to its business. The Standard is designed for the typical company in an industry, but individual companies may choose to report on different sustainability-related risks and opportunities based on their unique business model.

Disclosure Topics

What is the relationship between General Issue Category and Disclosure Topics? The General Issue Category is an industry-agnostic version of the Disclosure Topics that appear in each SASB Standard. Disclosure topics represent the industry-specific impacts of General Issue Categories. The industry-specific Disclosure Topics ensure each SASB Standard is tailored to the industry, while the General Issue Categories enable comparability across industries. For example, Health & Nutrition is a disclosure topic in the Non-Alcoholic Beverages industry, representing an industry-specific measure of the general issue of Customer Welfare. The issue of Customer Welfare, however, manifests as the Counterfeit Drugs disclosure topic in the Biotechnology & Pharmaceuticals industry.
  • Electronic Manufacturing Services & Original Design Manufacturing Remove
    Access Standard
    • Water & Wastewater Management The category addresses a company’s water use, water consumption, wastewater generation, and other impacts of operations on water resources, which may be influenced by regional differences in the availability and quality of and competition for water resources. More specifically, it addresses management strategies including, but not limited to, water efficiency, intensity, and recycling. Lastly, the category also addresses management of wastewater treatment and discharge, including groundwater and aquifer pollution.
      • Water Management The manufacturing of computers, computer components and other electronics requires significant volumes of water. Water is becoming a globally scarce resource because of increasing consumption from population growth, rapid urbanisation and climate change. Without careful planning, water scarcity may result in higher supply costs, social tensions with local communities and governments, or loss of access to water in water-scarce regions thereby presenting a critical risk to production and revenue. Electronic Manufacturing Services (EMS) & Original Design Manufacturing (ODM) entities that improve water use efficiency may reduce operating costs and maintain a lower risk profile, ultimately affecting cost of capital and market valuation. Furthermore, entities that prioritise water use efficiency may reduce regulatory risks as applicable jurisdictional environmental laws or regulations place more emphasis on resource conservation.
    • Waste & Hazardous Materials Management The category addresses environmental issues associated with hazardous and non-hazardous waste generated by companies. It addresses a company’s management of solid wastes in manufacturing, agriculture, and other industrial processes. It covers treatment, handling, storage, disposal, and regulatory compliance. The category does not cover emissions to air or wastewater nor does it cover waste from end-of-life of products, which are addressed in separate categories.
      • Waste Management The manufacturing of computers, computer components and other electronics requires significant volumes of chemicals and generates air and water emissions and solid waste, including hazardous substances. The handling and disposal of hazardous wastes produced during manufacturing may result in increased operating costs, capital expenditures, and in some instances, increased compliance costs or regulatory fines and penalties. Entities in the Electronic Manufacturing Services (EMS) & Original Design Manufacturing (ODM) industry that reduce waste produced during manufacturing and ensure it is appropriately reused, recycled or disposed may have a lower risk profile and face lower regulatory risks as applicable jurisdictional environmental laws or regulations place increasing emphasis on resource conservation and waste management.
    • Human Rights & Community Relations The category addresses management of the relationship between businesses and the communities in which they operate, including, but not limited to, management of direct and indirect impacts on core human rights and the treatment of indigenous peoples. More specifically, such management may cover socio-economic community impacts, community engagement, environmental justice, cultivation of local workforces, impact on local businesses, license to operate, and environmental/social impact assessments. The category does not include environmental impacts such as air pollution or waste which, although they may impact the health and safety of members of local communities, are addressed in separate categories.
      None
    • Access & Affordability The category addresses a company’s ability to ensure broad access to its products and services, specifically in the context of underserved markets and/or population groups. It includes the management of issues related to universal needs, such as the accessibility and affordability of health care, financial services, utilities, education, and telecommunications.
      None
    • Product Quality & Safety The category addresses issues involving unintended characteristics of products sold or services provided that may create health or safety risks to end-users. It addresses a company’s ability to offer manufactured products and/or services that meet customer expectations with respect to their health and safety characteristics. It includes, but is not limited to, issues involving liability, management of recalls and market withdrawals, product testing, and chemicals/content/ingredient management in products.
      None
    • Customer Welfare The category addresses customer welfare concerns over issues including, but not limited to, health and nutrition of foods and beverages, antibiotic use in animal production, and management of controlled substances. The category addresses the company’s ability to provide consumers with manufactured products and services that are aligned with societal expectations. It does not include issues directly related to quality and safety malfunctions of manufactured products and services, but instead addresses qualities inherent to the design and delivery of products and services where customer welfare may be in question. The scope of the category also captures companies’ ability to prevent counterfeit products.
      None
    • Selling Practices & Product Labeling The category addresses social issues that may arise from a failure to manage the transparency, accuracy, and comprehensibility of marketing statements, advertising, and labeling of products and services. It includes, but is not limited to, advertising standards and regulations, ethical and responsible marketing practices, misleading or deceptive labeling, as well as discriminatory or predatory selling and lending practices. This may include deceptive or aggressive selling practices in which incentive structures for employees could encourage the sale of products or services that are not in the best interest of customers or clients.
      None
    • Labour Practices The category addresses the company’s ability to uphold commonly accepted labour standards in the workplace, including compliance with labour laws and internationally accepted norms and standards. This includes, but is not limited to, ensuring basic human rights related to child labour, forced or bonded labour, exploitative labour, fair wages and overtime pay, and other basic workers’ rights. It also includes minimum wage policies and provision of benefits, which may influence how a workforce is attracted, retained, and motivated. The category further addresses a company’s relationship with organized labour and freedom of association.
      • Labour Practices Electronic Manufacturing Services (EMS) & Original Design Manufacturing (ODM) entities operate in a highly cost competitive environment and are therefore sensitive to labour costs and risks. Additionally, customers commonly require entities to meet tight production deadlines for important product launches, such as releases of new technology by hardware entities. Combined, these factors increase the importance of entities maintaining good relations with labour. Poor labour relations may expose entities to work stoppages and production disruptions. Such disruptions may result in reduced near-term revenue, as well as possible adverse effects on long-term productivity because of lower employee morale. In addition to maintaining an entity’s brand value and social licence to operate, improvements in labour practices may mitigate production disruptions.
    • Employee Health & Safety The category addresses a company’s ability to create and maintain a safe and healthy workplace environment that is free of injuries, fatalities, and illness (both chronic and acute). It is traditionally accomplished through implementing safety management plans, developing training requirements for employees and contractors, and conducting regular audits of their own practices as well as those of their subcontractors. The category further captures how companies ensure physical and mental health of workforce through technology, training, corporate culture, regulatory compliance, monitoring and testing, and personal protective equipment.
      • Workforce Conditions, Health & Safety The treatment of workers and the protection of workers’ rights in the Electronic Manufacturing Services (EMS) & Original Design Manufacturing (ODM) industry is of growing concern among customers, regulators and leading entities. Critical aspects of this issue may include working conditions, environmental responsibility and workforce health and safety—particularly relating to hazardous materials and potentially dangerous manufacturing equipment. Entities in this industry operate in a cost competitive environment and therefore rely upon low-cost and contract labour. The industry’s reliance on subcontractors, labour recruitment entities and a multi-tiered system of suppliers may make safety performance improvement difficult. Further, entities often are located in countries with relatively low direct costs and varying degrees of regulation and enforcement for protecting workers. This dynamic may increase an entity’s exposure to reputational risks and impacts on short- and long-term costs and sales. Such effects may result from increasing regulation and enforcement in response to high-profile safety or labour incidents, or through a shift in demand away from entities associated with such incidents. Entities with strong supply-chain standards, monitoring and engagement with suppliers to manage labour concerns may better protect shareholder value over the long term.
    • Employee Engagement, Diversity & Inclusion The category addresses a company’s ability to ensure that its culture and hiring and promotion practices embrace the building of a diverse and inclusive workforce that reflects the makeup of local talent pools and its customer base. It addresses the issues of discriminatory practices on the bases of race, gender, ethnicity, religion, sexual orientation, and other factors.
      None
    • Product Design & Lifecycle Management The category addresses incorporation of environmental, social, and governance (ESG) considerations in characteristics of products and services provided or sold by the company. It includes, but is not limited to, managing the lifecycle impacts of products and services, such as those related to packaging, distribution, use-phase resource intensity, and other environmental and social externalities that may occur during their use-phase or at the end of life. The category captures a company’s ability to address customer and societal demand for more sustainable products and services as well as to meet evolving environmental and social regulation. It does not address direct environmental or social impacts of the company’s operations nor does it address health and safety risks to consumers from product use, which are covered in other categories.
      • Product Lifecycle Management Entities in the Electronic Manufacturing Services (EMS) & Original Design Manufacturing (ODM) industry, along with the industry’s customers such as hardware entities, face increasing challenges associated with environmental externalities attributed to product manufacturing, transport, use and disposal. Rapid obsolescence of hardware products may worsen such externalities. The industry’s products commonly contain hazardous materials, making safe end-of-life disposal a critical aspect to manage. Entities unable to minimise the environmental externalities of their products may face increased regulatory costs as jurisdictional environmental laws or regulations place more emphasis on resource conservation and waste management. Through product innovation that facilitates end-of-life product recovery and the use of less impactful materials, EMS & ODM manufacturers can achieve improvements in lifecycle impacts, reduce regulatory risks and realise cost savings.
    • Supply Chain Management The category addresses management of environmental, social, and governance (ESG) risks within a company’s supply chain. It addresses issues associated with environmental and social externalities created by suppliers through their operational activities. Such issues include, but are not limited to, environmental responsibility, human rights, labour practices, and ethics and corruption. Management may involve screening, selection, monitoring, and engagement with suppliers on their environmental and social impacts. The category does not address the impacts of external factors – such as climate change and other environmental and social factors – on suppliers’ operations and/or on the availability and pricing of key resources, which is covered in a separate category.
      None
    • Materials Sourcing & Efficiency The category addresses issues related to the resilience of materials supply chains to impacts of climate change and other external environmental and social factors. It captures the impacts of such external factors on operational activity of suppliers, which can further affect availability and pricing of key resources. It addresses a company’s ability to manage these risks through product design, manufacturing, and end-of-life management, such as by using of recycled and renewable materials, reducing the use of key materials (dematerialization), maximizing resource efficiency in manufacturing, and making R&D investments in substitute materials. Additionally, companies can manage these issues by screening, selection, monitoring, and engagement with suppliers to ensure their resilience to external risks. It does not address issues associated with environmental and social externalities created by operational activity of individual suppliers, which is covered in a separate category.
      • Materials Sourcing Entities in the Electronic Manufacturing Services (EMS) & Original Design Manufacturing (ODM) industry rely on numerous critical materials as important inputs for finished products. Many of these inputs have few or no available substitutes and often are sourced in a few countries, many of which may be subject to geopolitical uncertainty. Other sustainability impacts related to climate change, land use, resource scarcity and conflict in regions where the industry’s supply chain operates are also increasingly shaping the industry’s ability to source materials. Additionally, increased competition for these materials because of growing global demand from other sectors may result in price increases and supply risks. Since entities commonly source materials from supply chains that often lack transparency, they may face increasing difficulty managing potential materials shortages, supply disruptions, price volatility and reputational risks. Failure to effectively manage sourcing may constrain access to necessary materials, reduce margins, impair revenue growth or increase costs of capital.
    • Business Ethics The category addresses the company’s approach to managing risks and opportunities surrounding ethical conduct of business, including fraud, corruption, bribery and facilitation payments, fiduciary responsibilities, and other behaviour that may have an ethical component. This includes sensitivity to business norms and standards as they shift over time, jurisdiction, and culture. It addresses the company’s ability to provide services that satisfy the highest professional and ethical standards of the industry, which means to avoid conflicts of interest, misrepresentation, bias, and negligence through training employees adequately and implementing policies and procedures to ensure employees provide services free from bias and error.
      None
  • Biotechnology & Pharmaceuticals Remove
    Access Standard
    • Water & Wastewater Management The category addresses a company’s water use, water consumption, wastewater generation, and other impacts of operations on water resources, which may be influenced by regional differences in the availability and quality of and competition for water resources. More specifically, it addresses management strategies including, but not limited to, water efficiency, intensity, and recycling. Lastly, the category also addresses management of wastewater treatment and discharge, including groundwater and aquifer pollution.
      None
    • Waste & Hazardous Materials Management The category addresses environmental issues associated with hazardous and non-hazardous waste generated by companies. It addresses a company’s management of solid wastes in manufacturing, agriculture, and other industrial processes. It covers treatment, handling, storage, disposal, and regulatory compliance. The category does not cover emissions to air or wastewater nor does it cover waste from end-of-life of products, which are addressed in separate categories.
      None
    • Human Rights & Community Relations The category addresses management of the relationship between businesses and the communities in which they operate, including, but not limited to, management of direct and indirect impacts on core human rights and the treatment of indigenous peoples. More specifically, such management may cover socio-economic community impacts, community engagement, environmental justice, cultivation of local workforces, impact on local businesses, license to operate, and environmental/social impact assessments. The category does not include environmental impacts such as air pollution or waste which, although they may impact the health and safety of members of local communities, are addressed in separate categories.
      • Safety of Clinical Trial Participants Clinical trials are an essential part of the biotechnology and pharmaceutical products approval process. Clinical trial participant safety is a critical component of an entity’s ability to bring a product to market successfully. Oversight of these trials is an important factor in the industry because of the numerous clinical trials conducted by third-party contract research organisations. Biotechnology & Pharmaceuticals entities that manage clinical trials effectively may enhance shareholder value through the incremental revenue associated with new products.
    • Access & Affordability The category addresses a company’s ability to ensure broad access to its products and services, specifically in the context of underserved markets and/or population groups. It includes the management of issues related to universal needs, such as the accessibility and affordability of health care, financial services, utilities, education, and telecommunications.
      • Access to Medicines Biotechnology and pharmaceuticals entities play an important role in providing access to the industry’s products around the world. Entities may develop product pricing frameworks that account for varying levels of economic development and different health care needs across various countries. Strategies related to improving access to medicines may yield growth opportunities, innovation and unique partnerships, which may enhance shareholder value.
      • Affordability & Pricing Stakeholder emphasis on health care cost containment and increased access may continue to place downward pricing pressures on the Biotechnology & Pharmaceuticals industry. As a result, entities that have relied on raising drug prices, contractual advantages and reverse payments to protect profits may be challenged by efforts to reduce costs. Entities that effectively manage their global pricing practices and associated stakeholder scrutiny of pricing practices may limit their risk exposure to regulatory action or adverse reputational effects.
    • Product Quality & Safety The category addresses issues involving unintended characteristics of products sold or services provided that may create health or safety risks to end-users. It addresses a company’s ability to offer manufactured products and/or services that meet customer expectations with respect to their health and safety characteristics. It includes, but is not limited to, issues involving liability, management of recalls and market withdrawals, product testing, and chemicals/content/ingredient management in products.
      • Drug Safety Important product safety information may be discovered after controlled clinical trials and regulatory approval. Subsequently, entities may be exposed to the financial implications of associate adverse events and product recalls. Product safety concerns, manufacturing defects or inadequate disclosure of product-related risks may result in significant product liability claims. Biotechnology & Pharmaceuticals entities that mitigate the incidence of product recalls, safety concerns and enforcement actions may better preserve shareholder value. In addition, concern over the abuse or resale of certain medications has resulted in the development of mandated take-back programmes. Entities that successfully engage in these programmes may limit future liabilities.
    • Customer Welfare The category addresses customer welfare concerns over issues including, but not limited to, health and nutrition of foods and beverages, antibiotic use in animal production, and management of controlled substances. The category addresses the company’s ability to provide consumers with manufactured products and services that are aligned with societal expectations. It does not include issues directly related to quality and safety malfunctions of manufactured products and services, but instead addresses qualities inherent to the design and delivery of products and services where customer welfare may be in question. The scope of the category also captures companies’ ability to prevent counterfeit products.
      • Counterfeit Drugs Fake or substandard medication presents a significant risk to consumers in all countries. Biotechnology & Pharmaceuticals entities may face added costs as jurisdictions implement drug supply chain regulations to prevent counterfeit, substandard or mislabelled drugs from entering the pharmaceutical distribution system. Entities that fail to manage this issue effectively may face material risks associated with the loss of public confidence and reduced revenue.
    • Selling Practices & Product Labeling The category addresses social issues that may arise from a failure to manage the transparency, accuracy, and comprehensibility of marketing statements, advertising, and labeling of products and services. It includes, but is not limited to, advertising standards and regulations, ethical and responsible marketing practices, misleading or deceptive labeling, as well as discriminatory or predatory selling and lending practices. This may include deceptive or aggressive selling practices in which incentive structures for employees could encourage the sale of products or services that are not in the best interest of customers or clients.
      • Ethical Marketing Biotechnology & Pharmaceuticals entities face challenges associated with the marketing of specific products. Direct-to-consumer advertisements for prescription drugs provide opportunities for increasing market share. However, marketing off-label uses may result in significant fines and settlements. Corporate disclosure of legal and regulatory fines and the codes of ethics that govern marketing activities may allow investors to better understand performance in this area.
    • Labour Practices The category addresses the company’s ability to uphold commonly accepted labour standards in the workplace, including compliance with labour laws and internationally accepted norms and standards. This includes, but is not limited to, ensuring basic human rights related to child labour, forced or bonded labour, exploitative labour, fair wages and overtime pay, and other basic workers’ rights. It also includes minimum wage policies and provision of benefits, which may influence how a workforce is attracted, retained, and motivated. The category further addresses a company’s relationship with organized labour and freedom of association.
      None
    • Employee Health & Safety The category addresses a company’s ability to create and maintain a safe and healthy workplace environment that is free of injuries, fatalities, and illness (both chronic and acute). It is traditionally accomplished through implementing safety management plans, developing training requirements for employees and contractors, and conducting regular audits of their own practices as well as those of their subcontractors. The category further captures how companies ensure physical and mental health of workforce through technology, training, corporate culture, regulatory compliance, monitoring and testing, and personal protective equipment.
      None
    • Employee Engagement, Diversity & Inclusion The category addresses a company’s ability to ensure that its culture and hiring and promotion practices embrace the building of a diverse and inclusive workforce that reflects the makeup of local talent pools and its customer base. It addresses the issues of discriminatory practices on the bases of race, gender, ethnicity, religion, sexual orientation, and other factors.
      • Employee Recruitment, Development & Retention Biotechnology & Pharmaceuticals entities face intense competition for recruiting and retaining employees. The industry relies on highly skilled employees to develop new products, conduct clinical trials, manage government regulations and commercialise new products. Entities that attract and retain employees despite a constrained talent pool may be better positioned to protect and enhance shareholder value.
    • Product Design & Lifecycle Management The category addresses incorporation of environmental, social, and governance (ESG) considerations in characteristics of products and services provided or sold by the company. It includes, but is not limited to, managing the lifecycle impacts of products and services, such as those related to packaging, distribution, use-phase resource intensity, and other environmental and social externalities that may occur during their use-phase or at the end of life. The category captures a company’s ability to address customer and societal demand for more sustainable products and services as well as to meet evolving environmental and social regulation. It does not address direct environmental or social impacts of the company’s operations nor does it address health and safety risks to consumers from product use, which are covered in other categories.
      None
    • Supply Chain Management The category addresses management of environmental, social, and governance (ESG) risks within a company’s supply chain. It addresses issues associated with environmental and social externalities created by suppliers through their operational activities. Such issues include, but are not limited to, environmental responsibility, human rights, labour practices, and ethics and corruption. Management may involve screening, selection, monitoring, and engagement with suppliers on their environmental and social impacts. The category does not address the impacts of external factors – such as climate change and other environmental and social factors – on suppliers’ operations and/or on the availability and pricing of key resources, which is covered in a separate category.
      • Supply Chain Management For the Biotechnology & Pharmaceuticals industry, managing supply chain quality is essential for protecting consumer health and corporate value. Biotechnology and pharmaceuticals entities that fail to ensure quality throughout their supply chains may be susceptible to lost revenue, supply disruptions and reputational damage. Disclosure of supply chain audit programmes may provide investors with an understanding of how entities in this industry are protecting shareholder value.
    • Materials Sourcing & Efficiency The category addresses issues related to the resilience of materials supply chains to impacts of climate change and other external environmental and social factors. It captures the impacts of such external factors on operational activity of suppliers, which can further affect availability and pricing of key resources. It addresses a company’s ability to manage these risks through product design, manufacturing, and end-of-life management, such as by using of recycled and renewable materials, reducing the use of key materials (dematerialization), maximizing resource efficiency in manufacturing, and making R&D investments in substitute materials. Additionally, companies can manage these issues by screening, selection, monitoring, and engagement with suppliers to ensure their resilience to external risks. It does not address issues associated with environmental and social externalities created by operational activity of individual suppliers, which is covered in a separate category.
      None
    • Business Ethics The category addresses the company’s approach to managing risks and opportunities surrounding ethical conduct of business, including fraud, corruption, bribery and facilitation payments, fiduciary responsibilities, and other behaviour that may have an ethical component. This includes sensitivity to business norms and standards as they shift over time, jurisdiction, and culture. It addresses the company’s ability to provide services that satisfy the highest professional and ethical standards of the industry, which means to avoid conflicts of interest, misrepresentation, bias, and negligence through training employees adequately and implementing policies and procedures to ensure employees provide services free from bias and error.
      • Business Ethics Biotechnology & Pharmaceuticals entities are subject to various jurisdictional laws and regulations pertaining to bribery, corruption and health care fraud and abuse. The ability of entities to ensure compliance throughout their global and domestic operational footprint may have material implications. Corporate disclosure of legal and regulatory fines and the codes of ethics that govern their interactions with health care professionals may allow investors to monitor performance in this area.

Select up to 4 industries

Current Industries:
Electronic Manufacturing Services & Original Design Manufacturing
|
Biotechnology & Pharmaceuticals
Health Care
Technology & Communications
Consumer Goods
Extractives & Minerals Processing
Financials
Food & Beverage
Infrastructure
Renewable Resources & Alternative Energy
Resource Transformation
Services
Transportation